Abstract: Clinical Analysis of 170 Patients with Bronchioloalveolar Cell CarcinomaZhihong XU1, Jia'an HU1, Junjie CHEN2, Fan CAI1, Jian REN3Correspondence to: Jia'an HU, E-mail: jahu_rj@yahoo.com.cn1Department of Geriatrics, Shanghai Ruijin Hospital of Shanghai Jiaotong University, Shanghai 200025, China2Department of Pathology, Shanghai Ruijin Hospital of Shanghai Jiaotong University, Shanghai 200025, China3Department of Thoracic Surgery, Shanghai Ruijin Hospital of Shanghai Jiaotong University, Shanghai 200025, ChinaAbstract Objective: To investigate clinical symptoms, radiological and pathological characteristics, and prognostic factors ofbronchioloalveolar cell carcinoma (BAC). Methods: Clinical data of 170 BAC patients admitted to our hospital between January 2000and June 2010 were retrospectively analyzed based on 2009 IASLC TNM Classification. The mono-factorial survival curve was plottedwith the Kaplan-Meier method. The variance associated with prognosis was evaluated by Log-rank test. A multivariate analysis of prog-nostic factors was performed with Cox proportional hazard regression model. Results: The male-to-female ratio was 1:1.4, and the ratioof smokers to non-smokers was 1:2.9. The median survival time was 6.48 years. Simple BAC and adenoma with BAC had little correla-tion with smoking. There was statistical significance in the intergroup survival curves among the pathological type, radiological typeand therapeutic regimen ( P < 0.05 ). Multivariate analysis indicated that pathological type, radiological type, TNM staging and mode oftreatment may correlate to the prognosis of BAC patients. However, sex, age and targeted therapy were not related to the survival ofthese patients. Conclusion: The incidence of BAC is common in non-smokers. Patients with simple BAC has a longer survival com-pared with those with BAC of other pathological types. Large amount of foamy sputum is not commonly seen in BAC patients. Thetreatment of choice for this disease is surgery with adjuvant therapy such as chemotherapy, radiotherapy, and molecular targeted thera-py. EGFR—TK1 is recommended as the first-line treatment for advanced BAC patients.Keywords Lung cancer; Bronchioalveolar carcinoma; Prognosis; Survival